Mark H. O’Hara

5.8k total citations · 2 hit papers
90 papers, 3.0k citations indexed

About

Mark H. O’Hara is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Mark H. O’Hara has authored 90 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 23 papers in Cancer Research and 18 papers in Molecular Biology. Recurrent topics in Mark H. O’Hara's work include Pancreatic and Hepatic Oncology Research (29 papers), Cancer Immunotherapy and Biomarkers (24 papers) and CAR-T cell therapy research (23 papers). Mark H. O’Hara is often cited by papers focused on Pancreatic and Hepatic Oncology Research (29 papers), Cancer Immunotherapy and Biomarkers (24 papers) and CAR-T cell therapy research (23 papers). Mark H. O’Hara collaborates with scholars based in United States, Austria and United Kingdom. Mark H. O’Hara's co-authors include Robert H. Vonderheide, Adham S. Bear, Gregory L. Beatty, Gabriela Plesa, Simon F. Lacey, Carl H. June, Thomas B. Karasic, Bruce L. Levine, Ursina Teitelbaum and Anne Marie Nelson and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Mark H. O’Hara

85 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

2020 398 citations Adham S. Bear, Robert H. Vonderheide et al. profile →
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

2018 379 citations Gregory L. Beatty, Mark H. O’Hara et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark H. O’Hara United States	26	2.2k	938	779	615	469	90	3.0k
Dominic G. Rothwell United Kingdom	25	1.3k 0.6×	1.1k 1.2×	317 0.4×	863 1.4×	327 0.7×	63	2.3k
Virginia Savova United States	14	566 0.3×	1.4k 1.5×	899 1.2×	345 0.6×	308 0.7×	27	2.7k
Jeffrey M. Granja United States	14	1.3k 0.6×	1.7k 1.8×	1.1k 1.4×	469 0.8×	183 0.4×	17	3.0k
Stephanie L. Goff United States	22	2.0k 0.9×	793 0.8×	1.4k 1.8×	156 0.3×	309 0.7×	48	2.8k
Martina Rudelius Germany	31	902 0.4×	1.1k 1.2×	590 0.8×	366 0.6×	245 0.5×	89	3.0k
Elias Sayour United States	25	1000 0.5×	657 0.7×	962 1.2×	182 0.3×	408 0.9×	81	2.0k
Mikhail Doubrovin United States	26	1.2k 0.5×	1.4k 1.5×	548 0.7×	436 0.7×	424 0.9×	65	3.3k
Kim Monkhorst Netherlands	28	1.8k 0.8×	986 1.1×	455 0.6×	665 1.1×	183 0.4×	112	3.4k
Yuru Meng United States	15	3.0k 1.4×	856 0.9×	2.7k 3.5×	306 0.5×	233 0.5×	18	4.4k
Olga Shestova United States	27	1.7k 0.8×	1.9k 2.0×	1.5k 1.9×	192 0.3×	318 0.7×	71	4.0k

Countries citing papers authored by Mark H. O’Hara

Since Specialization

Citations

This map shows the geographic impact of Mark H. O’Hara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark H. O’Hara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark H. O’Hara more than expected).

Fields of papers citing papers by Mark H. O’Hara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark H. O’Hara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark H. O’Hara. The network helps show where Mark H. O’Hara may publish in the future.

Co-authorship network of co-authors of Mark H. O’Hara

This figure shows the co-authorship network connecting the top 25 collaborators of Mark H. O’Hara. A scholar is included among the top collaborators of Mark H. O’Hara based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark H. O’Hara. Mark H. O’Hara is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chapin, William J., Wei‐Ting Hwang, Ronac Mamtani, & Mark H. O’Hara. (2024). Low- vs High-Dose 5-FU in Triplet Chemotherapy Plus Bevacizumab for Patients With Colorectal Cancer. JAMA Network Open. 7(7). e2424855–e2424855. 1 indexed citations

O’Hara, Mark H., Opeyemi A. Jegede, Mark A. Dickson, et al.. (2024). Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C. Clinical Cancer Research. 31(1). 56–64. 1 indexed citations

Bear, Adham S., Mark H. O’Hara, Chong Xu, et al.. (2024). Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. Journal of Clinical Investigation. 134(21). 12 indexed citations

O’Hara, Mark H., Ursina Teitelbaum, Thomas B. Karasic, et al.. (2024). A phase II study of maintenance rucaparib in patients with platinum sensitive, advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2 or PALB2: A four year survival update.. Journal of Clinical Oncology. 42(3_suppl). 661–661. 1 indexed citations

Brown, Timothy J., Arielle Yablonovitch, Jacob E. Till, et al.. (2023). The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib. Clinical Cancer Research. 29(24). 5207–5216. 10 indexed citations

O’Hara, Mark H., Max M. Wattenberg, Ignacio Garrido‐Laguna, et al.. (2023). A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.. Journal of Clinical Oncology. 41(16_suppl). TPS4201–TPS4201. 1 indexed citations

Tanyi, János L., Mark H. O’Hara, Elizabeth O. Hexner, et al.. (2023). 671 Phase 1 trial of human chimeric antigen receptor modified T cells (huCART-meso) administered in combination with oncolytic virus VCN-01 in patients with pancreatic and ovarian cancer. SHILAP Revista de lepidopterología. A760–A761.

Mioduszewska, Berenika, et al.. (2022). The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups. Journal of Visualized Experiments. 1 indexed citations

Bear, Adham S., Tatiana Blanchard, Michael Ford, et al.. (2021). Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nature Communications. 12(1). 4365–4365. 73 indexed citations

10.

O’Hara, Mark H., Berenika Mioduszewska, Roger Mundry, et al.. (2021). Wild Goffin’s cockatoos flexibly manufacture and use tool sets. Current Biology. 31(20). 4512–4520.e6. 25 indexed citations

11.

Yu, Shun, Ronac Mamtani, Mark H. O’Hara, et al.. (2021). Comparative Effectiveness of Total Neoadjuvant Therapy Versus Standard Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. Clinical Colorectal Cancer. 20(2). 121–129. 7 indexed citations

12.

Till, Jacob E., Taylor A. Black, Caren Gentile, et al.. (2021). Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis. Journal of Molecular Diagnostics. 23(11). 1545–1552. 9 indexed citations

13.

Yang, Zijian, Michael J. LaRiviere, Jina Ko, et al.. (2020). A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 26(13). 3248–3258. 87 indexed citations

14.

Luo, Leo Y., Mark H. O’Hara, Tara C. Mitchell, et al.. (2020). Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. Seminars in Radiation Oncology. 30(2). 173–180. 8 indexed citations

15.

Ko, Andrew H., Alexander C. Jordan, Simon F. Lacey, et al.. (2020). Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Molecular Therapy. 28(11). 2367–2378. 42 indexed citations

16.

Hays, John L., Jordan Berlin, Mark H. O’Hara, et al.. (2018). Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC). Annals of Oncology. 29. viii716–viii716. 3 indexed citations

17.

Maity, Amit, Rosemarie Mick, Alexander C. Huang, et al.. (2018). A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. British Journal of Cancer. 119(10). 1200–1207. 79 indexed citations

18.

O’Hara, Mark H., Stanley R. Hamilton, & Peter J. O’Dwyer. (2016). Molecular Triage Trials in Colorectal Cancer. The Cancer Journal. 22(3). 218–222. 1 indexed citations

19.

Beatty, Gregory L. & Mark H. O’Hara. (2016). Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacology & Therapeutics. 166. 30–39. 109 indexed citations

20.

O’Hara, Mark H., et al.. (2007). Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). Translational Lung Cancer Research. 6(2). 159–168. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact